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Abstract 
Background: Many investigators detected the simian polyomavirus SV40 footprints in human brain tumors and 
neurologic diseases and recently it has been indicated that SV40 seems to be associated with multiple sclerosis (MS) 
disease. Interestingly, SV40 interacts with human leukocyte antigen (HLA) class I molecules for cell entry. HLA class I 
antigens, in particular non-classical HLA-G molecules, characterized by an immune-regulatory function, are involved 
in MS disease, and the levels of these molecules are modified according with the disease status.
Objective: We investigated in serum samples, from Italian patients affected by MS, other inflammatory diseases 
(OIND), non-inflammatory neurological diseases (NIND) and healthy subjects (HS), SV40-antibody and soluble sHLA-G 
and the association between SV40-prevalence and sHLA-G levels.
Methods: ELISA tests were used for SV40-antibodies detection and sHLA-G quantitation in serum samples.
Results: The presence of SV40 antibodies was observed in 6 % of patients affected by MS (N = 4/63), 10 % of OIND 
(N = 8/77) and 15 % of NIND (N = 9/59), which is suggestive of a lower prevalence in respect to HS (22 %, N = 18/83). 
MS patients are characterized by higher sHLA-G serum levels (13.9 ± 0.9 ng/ml; mean ± St. Error) in comparison 
with OIND (6.7 ± 0.8 ng/ml), NIND (2.9 ± 0.4 ng/ml) and HS (2.6 ± 0.7 ng/ml) subjects. Interestingly, we observed an 
inverse correlation between SV40 antibody prevalence and sHLA-G serum levels in MS patients.
Conclusion: The data obtained showed a low prevalence of SV40 antibodies in MS patients. These results seems 
to be due to a generalized status of inability to counteract SV40 infection via antibody production. In particular, we 
hypothesize that SV40 immune-inhibitory direct effect and the presence of high levels of the immune-inhibitory 
HLA-G molecules could co-operate in impairing B lymphocyte activation towards SV40 specific peptides.
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Background
Multiple sclerosis (MS) is an inflammatory chronic 
demyelinating human disease of the central nervous 
system (CNS) characterized by an autoimmune patho-
genic process in genetically predisposed individuals [1]. 
Infectious agents are environmental factors potentially 
involved in the MS onset. Distinct human viruses were 
found to be associated with MS, such as herpesviruses 
and retroviruses [2].
A recent study indicated that the simian polyomavirus 
SV40 seems to be associated with MS disease [3]. SV40, 
a neurotropic polyomavirus, is the causative viral agent 
of the progressive multifocal leukoencephalopathy (PML) 
in immune-compromised macaques. Many investigators 
detected SV40 footprints in human brain tumors and 
neurologic diseases [4]. SV40, as an adventitious virus, 
was present in early anti-polio vaccines administered to 
different human populations in the period 1955–1963. It 
is also possible that this polyomavirus was already pre-
sent in humans, as unknown virus. Interestingly, SV40 
interacts with human leukocyte antigen (HLA) class I 
molecules for cell entry [5]. After binding to class I mol-
ecules, SV40 enters cells via a unique endocytic pathway 
that involves caveolae and delivers SV40 to the endoplas-
mic reticulum. Although class I molecules bind SV40, 
they do not enter with SV40. Instead, they are shed from 
the cell surface by the activity of metalloproteases. HLA 
class I antigens, in particular non-classical HLA-G mol-
ecules, are involved in MS disease, and the levels of these 
molecules are modified according with the disease status 
[6–8]. HLA-G is characterized by the presence of mem-
brane (m) bound (G1–G4) and soluble (s) (G5–G7) iso-
forms [6]. HLA-G is involved in mechanisms of immune 
tolerance in pregnancy, organ transplantation, autoim-
mune and inflammatory diseases by inhibiting cytolytic 
functions of natural killer cells, cytotoxic T lympho-
cytes, T and dendritic cells allo-proliferation [7]. Solu-
ble and membrane-bound HLA-G isoforms have similar 
functions and interact with specific inhibitory receptors 
(ILT-2 and ILT-4) expressed by immune cells [9]. HLA-G 
has an important role in MS: (i) cerebrospinal fluid (CSF) 
levels and the intrathecal synthesis of sHLA-G are higher 
in MS patients in comparison with controls and are asso-
ciated with clinical and radiological evidence of disease 
remission (ii) elevated sHLA-G concentrations in CSF 
correlated with the presence of an anti-inflammatory 
and pro-apoptotic intrathecal microenvironment, (iii) 
HLA-G expression is high within and around MS lesions 
and (iv) HLA-G +  regulatory T cells highly represented 
in brain lesions of MS patients [8].
Interesting, during viral infections, HLA-G molecules 
are up-regulated by the virus as a mechanism of immune-
escape [7] inhibiting the host immune response.
The recent development of specific and sensitive sero-
logic test for SV40, that has allowed the detection of 
specific serum antibodies against SV40 VPs [1] and 
the possibility to evaluate the levels of soluble HLA-G 
expression in biological fluids [8], suggested the analysis 
of these two components in sera from MS patients.
The objective of the present study was to investigate 
whether serum samples from Italian patients affected by 
MS, other inflammatory diseases (OIND), non-inflam-
matory neurological diseases (NIND) and healthy sub-
jects (HS) (i) carry SV40-antibodies, (ii) present different 
levels of soluble HLA-G molecules, (iii) the existence of 
an association between SV40-antobody prevalence and 
sHLA-G levels. The data obtained are relevant to under-
stand the possible implication of SV40 infection and host 
immune response in MS disease.
Methods
Human samples
Serum samples (n  =  282), collected at the University 
Hospital of Ferrara, Department of Neurology and Clini-
cal Laboratory Analysis, were from our collections [3]. 
Human sera were from discarded clinical laboratory anal-
ysis samples, anonymously collected, coded with indica-
tions of age, gender and pathology, if any. Sera from MS 
patients (n = 63), mean age = 39 ± 26 years, as well as 
from other inflammatory neurologic dideases (OIND) 
(n  =  77), mean age  =  53  ±  10  years, and non-inflam-
matory neurologic diseases (NIND) (n  =  59) affected 
patients, mean age = 54 ± 12 years, and healthy subjects 
(HS) (n = 83), mean age = 66 ± 5 years. Informed written 
consent was obtained by patients/individuals. The project 
was approved by the Ethics Committee, Ferrara, Italy.
Synthetic peptides
Computer assisted analyses allowed the selection of two 
specific SV40 peptides, from the late viral region that did 
not cross-react with the BKV and JCV hyperimmune sera 
[1]. The two peptides belong to the VP1/VP2/VP3 viral 
capsid proteins (VP1 ID: 1489598; VP3 ID: 9486895; 
http://www.ncbi.nlm.nih.gov/nuccore). The amino acid 
sequences of the two peptides, known as VP1 B and 
VP2/3 C, respectively, are as follows:
VP1 B: 
NH2–NPDEHQKGLSKSLAAEKQFTDDSP–COOH
VP2/3 C: 
NH2–IQNDIPRLTSQELERRTQRYLRD–COOH
VP1 B and VP2/3 C mimotopes were selected as they 
react specifically in indirect ELISA with the rabbit hyper-
immune serum that had been experimentally immunized 
with SV40 (positive control serum) and the amino acid 
residues of these two specific SV40 VP peptides show low 
homology with the BKV, JCV and other polyomaviruses 
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VPs. SV40-positive and SV40-negative human sera were 
also employed as controls. These SV40 control sera, 
selected by the neutralization assay, were from our col-
lections (see below the other technical details). BKV and 
JCV hyperimmune rabbit sera did not react with VP1 
B or VP2/3 C peptides (negative control sera). The syn-
thetic peptides were synthesized using standard proce-
dures (UFPeptides s.r.l., Ferrara, Italy).
Indirect enzyme‑linked immunosorbent assay (ELISA)
Indirect ELISA with the mimotopes specific for the region 
of SV40 VPs were carried out as previously described [1]. 
We used as positive-control an immune rabbit serum con-
taining anti-SV40 antibodies, as negative controls anti-
BKV and anti-JCV immune sera, and three human serum 
samples, which were found to be SV40 negative in our 
previous investigations [1]. SV40-positive sera had a gen-
eral cut-off, by spectrophotometric reading, in the range 
of 0.18 OD, that discriminates SV40-negative (OD < 0.18) 
from SV40-positive samples (OD  >  0.18). As published 
before, in indirect ELISAs the human peptide hNPS [1] 
which is unrelated to SV40, was employed as a negative 
control peptide. This negative control peptide does not 
react with SV40-positive and SV40-negative sera, with 
OD values usually in the range of 0.088–0.098, similar to 
the OD background of both human and rabbit sera.
SV40 specificity of the indirect ELISA employing synthetic 
peptides which mimic the VPs antigens
The identification and study of synthetic peptides was 
performed by comparative computer assisted analyses 
with BLAST program on the SV40 VP peptides VP1 B 
and VP2/3 C and the corresponding amino acid (a.a.) 
sequences of the new human polyomaviruses (HPyV) and 
hundreds of different BKV and JCV serotypes. Results 
indicate a low homology for the BKV and JCV prototypes 
and other polyomaviruses [1].
sHLA‑G detection by ELISA
sHLA-G concentrations were investigated in serum sam-
ples by enzyme immunosorbent assay, as reported in the 
Essen Workshop on sHLA-G quantification [10]. As cap-
ture antibody we used MEM-G9 MoAb (Exbio, Praha, 
CZ) and anti-beta2 microglobulin MoAb—HRP was used 
as detection antibody. The intra-assay coefficient of vari-
ation (CV) is 1.4 %, the inter-assay CV is 4.0 %. The limit 
of sensitivity is 1.0 ng/ml.
Statistical analyses
All analyses were performed by Prism 4.0 (GraphPad 
software). To determine significances we used two-sided 
Chi square test, Anova and Newman-Keuls comparison 
test, nonparametric Spearman analysis and Fisher’s exact 
test. For all tests, we considered p < 0.05 to be statistically 
significant.
Results
We evaluated SV40 antibodies seroprevalence and sHLA-
G serum levels in 4 cohorts of subjects: MS, OIND, NIND 
and HS subjects, matched for sex and age. Two indirect 
ELISAs, against two distinct SV40 viral capsid protein 
(VP) epitopes, named B and C, were employed to test 
serum samples. The two indirect ELISAs gave overlapping 
results. Serum samples, which reacted with both mimo-
topes, and considered SV40-positive, reached an over-
all prevalence of 6 % (4/63) in MS, 10 % (8/77) in OIND, 
15 % (9/59) in NIND and 22 % (18/83) in HS (Table 1). It 
is interesting to note that the percentage of seroprevalence 
in MS patients is much lower than that of HS subjects 
(p < 0.05; Fisher’s exact test) [3]. Among sera of the differ-
ent cohorts, MS, OIND, NIND, HS, 64 samples tested pos-
itive for the epitope B with a prevalence of 23 %, whereas 
54 samples tested positive for the epitope C with a preva-
lence of 19 %. The difference is not statistically significant 
(p  <  0.05, by Fisher’s exact test). The mean OD of sera 
(VPs B + C ± Std Error) in MS (0.20 ± 0.01) and OIND 
(0.21 ± 0.02) were lower than that in HS (0.41 ± 0.03) and 
in NIND (0.35  ±  0.024) subjects (Anova and Newman-
Keuls comparison test; p < 0.0001) (Table 1; Fig. 1a). 
Then, the same serum samples were analyzed by 
ELISA for the presence of sHLA-G molecules. All 
MS serum samples were positive for sHLA-G (63/63: 
Table 1 SV40 and sHLA-G results in MS, OIND, NIND and HS subjects
p values: * p < 0.05; ** p ≪ 0.0001; *** p <0.001
a Anova and Newman-Keuls comparison test
b Fisher exact test
SV40 Ab titre OD 
(mean ± Std error)a
SV40 Ab + (%)b SHLA‑G ng/ml
(mean ± Std error)a
SHLA‑G + (%)b <Cut off sHLA‑G 
(> 15 ng/ml)b
MS (63) 0.20 ± 0.01** 6* 13.9 ± 0.9 ng/ml** 100** 30***
OIND (77) 0.21 ± 0.02** 10* 6.7 ± 0.8 ng/ml 58 29***
NIND (59) 0.35 ± 0.024 15 2.9 ± 0.4 ng/ml 51 0
HS (83) 0.41 ± 0.03 22 2.6 ± 0.7 ng/ml 41 2
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100  %), whereas sHLA-G molecules were detected in 
58 % (45/77) of OIND, 51 % (20/59) of NIND and 41 % 
(35/83) of HS (p  <  0.0001; Fisher’s exact test) (Table  1). 
When we looked at sHLA-G expression, we observed 
higher mean sHLA-G levels in sera of MS (13.9 ± 0.9 ng/
ml) and OIND (6.7 ± 0.8 ng/ml) patients in comparison 
with NIND (2.9 ± 0.4 ng/ml) and HS (2.6 ± 0.7 ng/ml) 
subjects (Anova and Newman-Keuls comparison test; 
p  <  0.001) (Table  1; Fig  1b). These results are in agree-
ment with our previous data on higher sHLA-G levels in 
MS patients in comparison with control cohorts [7].
When we evaluated the 95 %CI of mean for choosing 
a cutoff point for sHLA-G levels that differentiates MS 
patients in comparison with control cohorts, we obtained 
the value of 15 ng/ml. We observed that MS patients pre-
sented levels of sHLA-G higher than the cutoff value in 
the 30 % (19/63) of samples, OIND in the 29 % (13/45), 
NIND in the 0  % (0/20) and HS in the 3  % (1/35). Of 
note, MS patients positive for the presence of antibodies 
reacting with SV40 mimotopes presented sHLA-G levels 
lower than 15  ng/ml, revealing an inverted correlation 
between the prevalence of antibodies reacting with SV40 
mimotopes and the sHLA-G levels. (Nonparametric cor-
relation Spearman analysis; r = 0.997, p = 0.0001).
On the contrary, no correlation between the presence 
of antibodies reacting with SV40 mimotopes and the 
sHLA-G levels was observed in control cohorts.
The originality of the findings reported herein is the 
inverted association between SV40 antibody preva-
lence and sHLA-G concentration detected in sera of MS 
patients.
Discussion
In this study, serum samples from patients affected by 
neurologic diseases, including MS, were analyzed for 
exposure to SV40 infection, as reported before [3]. In 
this investigation, serum samples were analyzed for 
the first time by ELISA to verify the sHLA-G levels. At 
the same time, samples belonging to the serum collec-
tion reported in a previous study [3] were re-analyzed 
by ELISA with SV40 synthetic peptides B and C for the 
viral antibody prevalence. The SV40 antibody preva-
lence detected herein did not differ statistically from 
early data [3].
Our immunologic data suggest that specific SV40 anti-
bodies are detectable in human serum samples from neu-
rologic patients and healthy individuals. Specifically, the 
presence of SV40 antibodies observed in patients affected 
by MS (6 %) revealed a lower prevalence of SV40 antibod-
ies in respect to controls, HS (22 %). It should be noted 
that MS patients included in our study, at the time of the 
serum collection, were not subjected to any immuno-
modulatory therapy and were in a remission phase of 
the disease. These data indicate that the low prevalence 
of SV40 antibodies is not due to the immune-modulatory 
therapy or to a status of reactivation of the disease. We 
hypothesize that patients affected by inflammatory neu-
rologic diseases, including MS, are unable to counteract 
SV40 infection via antibody production.
Our results on soluble HLA-G levels molecules support 
our previous data on HLA-G expression in MS patients 
[7]. In particular, MS patients are characterized by higher 
sHLA-G serum levels in comparison with OIND, NIND 
and healthy subjects. The increased expression of HLA-G 
secretion in MS and OIND patients could account for 
the inflammatory condition, that these patients try to 
Fig. 1 SV40 antibodies titres and sHLA-G levels in serum samples 
from from MS multiple sclerosis patients , OIND other inflammatory 
neurologic diseases , NIND non-inflammatory neurologic diseases 
and HS Healthy subjects. a SV40 antibodies titres are are presented as 
values of OD optical density readings at λ 405 nm of serum samples 
diluted at 1:20, detected in indirect ELISA. In scatter dot plotting, each 
plot represents the dispersion of OD values to a mean level indicated 
by the line inside the scatter with Standard Error Mean (SEM) for each 
group of subjects analyzed. b sHLA-G levels are presented as ng/ml in 
serum samples diluted at 1:2, detected in indirect ELISA. In scatter dot 
plotting, each plot represents the dispersion of sHLA-G values to a 
mean level indicated by the line inside the scatter with Standard Error 
Mean (SEM) for each group of subjects analyzed. Statistical analysis 
was performed using Anova and Newman-Keuls comparison test. 
(**p < 0.0001; *p < 0.001)
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counteract at the systemic level, via the production of an 
anti-inflammatory molecule.
The novelty of this research is the impressive inverse 
correlation between sHLA-G serum levels and the preva-
lence of SV40 antibodies in MS patients. In particular, we 
observed that MS patients positive for SV40 antibodies 
presented sHLA-G levels lower than 15 ng/ml, the cutoff 
point for sHLA-G levels that differentiate MS patients in 
comparison with NIND and HS cohorts. OIND patients 
behave similarly to MS patients, with a lower prevalence 
of antibodies reacting with SV40 mimotopes and >15 ng/
ml sHLA-G levels. In the other two cohorts, represented 
by NIND patients and HS, a higher prevalence of SV40 
antibodies and <15 ng/ml sHLA-G levels were revealed. 
These results suggest that the presence of >15 ng/ml lev-
els of sHLA-G seems to hamper the production of SV40 
antibodies, in a manner that remains to be elucidated. In 
this context, it should be recalled that the engagement of 
the surface Ig-like transcript 2 (ILT2) inhibitory receptor 
with its preferential ligand HLA-G is critical to inhibit 
B cell functions [9]. Indeed, ILT2-HLA-G interaction 
impedes both naive and memory B cell functions in vitro 
and in  vivo. Particularly, HLA-G inhibits B cell prolif-
eration, differentiation, and Ig secretion in both T cell-
dependent and -independent models of B cell activation. 
Interestingly, SV40 down-regulates the expression of 
CD83 and CD86 on dendritic cells (DC) and impairs DC-
induced activation of T cell and B cell proliferations [11]. 
These findings suggest that SV40 infection might also 
cause immune suppression by influencing differentiation 
and maturation of B cells. We may speculate that the low 
prevalence of SV40 specific antibodies in MS patients 
could be in part ascribed to SV40 immune-inhibitory 
direct effect and in part to the presence of  >15  ng/ml 
HLA-G levels that could impair B lymphocyte activa-
tion towards SV40 specific peptides. Since both MS dis-
ease and viral infection are characterized by an increase 
in HLA-G expression [7, 8] we could hypothesize a syn-
ergic effect of these two conditions in the maintenance 
of a dysregulated immune response in MS patients. To 
account this hypothesis, we will evaluated the same vari-
able in larger cohorts of subjects, correlating the results 
with clinical follow-up.
Conclusions
Our data confirm a low prevalence of SV40 antibodies in 
MS patients (3). These results seem to be due to a gener-
alized status of inability to counteract SV40 infection via 
antibody production. In particular, we hypothesize that 
SV40 immune-inhibitory direct effect and the presence 
of high levels of the immune-inhibitory HLA-G mole-
cules could co-operate in impairing B lymphocyte activa-
tion towards SV40 specific peptides. Our findings are of 
extreme interest to understand the possible role of SV40 
infection in the pathogenesis of MS disease and the effect 
of this virus on the host immune response.
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